Colleen McCabe, PharmD, BCOP, and Lindsay Mundy, PharmD, BCOP, led an engaging exploration of the benefits and potential pitfalls with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in an oncology setting in their presentation, GLP-1s in Oncology: Miracle, Misdirection, or Missed Opportunity
Lymph protects metastasizing melanoma cells from ferroptosis
Insert the needle into the top of your vial
Imagine having a team that stands by you, combining medical expertise with lifestyle modifications
Participants were more able to maintain reductions in weight if they switched to the once-daily oral GLP-1, rather than a placebo
Users describe improvements in digestive symptoms, reduced inflammation markers, and resolution of chronic gastrointestinal issues